SEC Form 4 · accession 0001209191-18-062940

ARENA PHARMACEUTICALS INC · ARNA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Dec 14, 2018

Accepted (ET)

Dec 17, 2018 · 4:25 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001080709

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Dec 14, 2018	A	1,825	$0.00	A	1,825	D
Common Stock^F2	Dec 14, 2018	A	1,825	$0.00	A	1,825	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F3	$41.09	Dec 14, 2018	A	2,500	A	—	Dec 14, 2025	Common Stock	2,500	2,500	D
Stock Option (right to buy)^F4	$41.09	Dec 14, 2018	A	2,500	A	—	Dec 14, 2025	Common Stock	2,500	2,500	D

F1The amount represents restricted stock units that vest in three equal installments on the dates of Arena's next three annual meetings of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units.
F2The amount represents restricted stock units that vest in full on the earliest of June 13, 2019, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units.
F3The options vest in 36 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over three years beginning on January 14, 2019, and are exercisable once vested.
F4The options vest in equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) beginning on the one-month anniversary of the grant date and ending on the one-year anniversary of our most recent annual meeting of stockholders, and are exercisable once vested.